Table 1.

Association between plasma enzymatic activity of AMY1 or AMY2 and metabolic traits in D.E.S.I.R.

Traits/disorders	AMY1			AMY2
	n	Effect size ± SEa	P value	n	Effect size ± SEa	P value
BMI (kg/m2)	3673	−0.0013 ± 0.0002	2.4 × 10−13	3905	−0.0024 ± 0.0003	2.0 × 10−16
FG (mmol/L)	3629	−0.0019 ± 0.0006	1.4 × 10−3	3860	−0.0026 ± 0.0010	9.2 × 10−3
FI (pmol/L)	3625	0.0003 ± 0.0006	0.63	3856	0.0025 ± 0.0009	7.5 × 10−3
HOMA-2B	3343	0.0010 ± 0.0004	9.0 × 10−3	3548	0.0017 ± 0.0006	4.6 × 10−3
HOMA-2IR	3343	0.0004 ± 0.0005	0.40	3548	0.0007 ± 0.0008	0.36
HDL (mmol/L)	3432	0.0015 ± 0.0005	2.1 × 10−3	3637	−0.0005 ± 0.0008	0.58
LDL (mmol/L)	3427	0.0006 ± 0.0011	0.61	3632	−0.0006 ± 0.0019	0.74
TG (mmol/L)	3463	0.0003 ± 0.0006	0.68	3673	0.0003 ± 0.0010	0.81
ApoB (g/L)	3463	0.0001 ± 0.0003	0.83	3673	−0.0008 ± 0.0005	0.11
ApoA1 (g/L)	3463	0.0008 ± 0.0003	0.016	3673	−0.0009 ± 0.0005	0.10
SBP (mm Hg)	3245	−0.0063 ± 0.017	0.71	3452	−0.067 ± 0.029	0.020
DBP (mm Hg)	3245	0.0010 ± 0.011	0.93	3452	−0.013 ± 0.019	0.48
GGT (IU/L)	3744	−0.0025 ± 0.042	0.95	3980	0.021 ± 0.075	0.79
ALT (IU/L)	3741	0.032 ± 0.021	0.13	3977	−0.025 ± 0.035	0.47
AST (IU/L)	3741	0.0017 ± 0.0004	4.1 × 10−5	3977	0.0002 ± 0.0007	0.76

^aEffect size according to adjusted linear regression model. BMI, AST, FI, HOMA-2B, HO MA-2IR, and TG were logarithmically transformed before statistical analysis

ALT alanine aminotransferase, AMY1 salivary amylase, AMY2 pancreatic amylase, ApoA1 apolipoprotein A1, ApoB apolipoprotein B, AST aspartate aminotransferase, BMI body mass index, CI confidence interval, DBP diastolic blood pressure, FG fasting plasma glucose, FI fasting serum insulin, GGT gamma-glutamyl transferase, HDL high-density lipoprotein, HOMA-2B homeostasis model assessment of beta-cell function, HOMA-2IR homeostasis model assessment of insulin resistance, LDL low-density lipoprotein cholesterol, SBP systolic blood pressure, SE standard error, TG triglyceride